Response to early treatment evaluated with 18F-FDG PET and PERCIST 1.0 predicts survival in patients with ewing sarcoma family of tumors treated with a monoclonal antibody to the insulinlike growth factor 1 receptor

Journal of Nuclear Medicine

Volumn 57, Issue 5, 2016, Pages 735-740

  Joo, Hyun O ^a   Luber, Brandon S ^a   Leal, Jeffrey P ^a   Wang, Hao ^a   Bolejack, Vanessa ^b   Schuetze, Scott M ^c   Schwartz, Lawrence H ^d   Helman, Lee J ^e   Reinke, Denise ^f   Baker, Laurence H ^c   Wahl, Richard L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d Howard Hughes Medical Institute   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f SARC   (United States)

Author keywords

18F FDG PET; Insulin like growth factor; Sarcoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; INSULIN LIKE GROWTH FACTOR 1 RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; SOMATOMEDIN C RECEPTOR;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; EARLY INTERVENTION; EWING SARCOMA; EWING SARCOMA FAMILY OF TUMOR; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; OVERALL SURVIVAL; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROGRESSIVE METABOLIC DISEASE; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RECURRENT EWING SARCOMA FAMILY OF TUMOR; REFRACTORY EWING SARCOMA FAMILY OF TUMOR; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LOCALIZATION; WORLD HEALTH ORGANIZATION; BONE NEOPLASMS; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; IMMUNOLOGY; INFANT; METABOLISM; MIDDLE AGED; PRESCHOOL CHILD; SARCOMA, EWING; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; GLUCOSE; HUMANS; INFANT; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, IGF TYPE 1; SARCOMA, EWING; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84967223153     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.162412     Document Type: Article

References (19)

1. Pappo AS, Patel SR, Crowley J, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: Results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol. 2011; 29:4541-4547.
2. Subbiah V, Kurzrock R. Phase 1 clinical trials for sarcomas: The cutting edge. Curr Opin Oncol. 2011;23:352-360.
3. Hawkins DS, Schuetze SM, Butrynski JE, et al. [18F]fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol. 2005;23:8828-8834.
4. Im HJ, Kim TS, Park SY, et al. Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma. Eur J Nucl Med Mol Imaging. 2012;39:39-49.
5. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(suppl 1):122S-150S.
6. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
7. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56:337-344.
8. Heagerty PJ, Zeger SL. Multivariate continuation ratio models: Connections and caveats. Biometrics. 2000;56:719-732.
9. Arnaldez FI, Helman LJ. Targeting the insulin growth factor receptor. Hematol Oncol Clin North Am. 2012;26:527-542.
10. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther. 2007;6:1-12.
11. Yee D. Insulin-like growth factor receptor inhibitors: Baby or the bathwater? J Natl Cancer Inst. 2012;104:975-981.
12. Gualberto A, Dolled-Filhart M, Gustavson M, et al. Molecular analysis of nonsmall cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin Cancer Res. 2010;16:4654-4665.
13. Schuetze SM, Rubin BP, Vernon C, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer. 2005;103:339-348.
14. Hawkins DS, Rajendran JG, Conrad EU, III, Bruckner JD, Eary JF. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-Dglucose positron emission tomography. Cancer. 2002;94:3277-3284.
15. Fahey FH, Kinahan PE, Doot RK, Kocak M, Thurston H, Poussaint TY. Variability in PET quantitation within a multicenter consortium. Med Phys. 2010;37: 3660-3666.
16. Møller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30:152-177.
17. Zander T, Scheffler M, Nogova L, et al. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [18F]fluorodeoxyglucose and [18F]fluorothymidine positron emission tomography. J Clin Oncol. 2011;29:1701-1708.
18. Prior JO, Montemurro M, Orcurto MV, et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol. 2009;27: 439-445.
19. Stroobants S, Goeminne J, Seegers M, et al. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer. 2003;39:2012-2020.